Evidence map›Paper›PMID 31254442›Full record

ArticleMolecular oncology2019

Detection of mutational patterns in cell-free DNA of colorectal cancer by custom amplicon sequencing.

Simon Herrmann, Tianzuo Zhan, Johannes Betge, Benedikt Rauscher, Sebastian Belle, Tobias Gutting, Nadine Schulte, Ralf Jesenofsky, Nicolai Härtel, Timo Gaiser and 3 more

Abstract read
In one paragraph

Article in Molecular oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Simon HerrmannDivision Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Tianzuo ZhanDivision Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Johannes BetgeDivision Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Benedikt RauscherDivision Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sebastian BelleDepartment of Internal Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Tobias GuttingDepartment of Internal Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Nadine SchulteDepartment of Internal Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Ralf JesenofskyDepartment of Internal Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Nicolai HärtelDepartment of Internal Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Timo GaiserMedical Faculty Mannheim, Institute of Pathology, Heidelberg University, Mannheim, Germany.
Ralf-Dieter HofheinzMedical Faculty Mannheim, Interdisciplinary Tumor Centre, Heidelberg University, Mannheim, Germany.
Matthias P EbertDepartment of Internal Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Michael BoutrosDivision Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monitoring the mutational patterns of solid tumors during cancer therapy is a major challenge in oncology. Analysis of mutations in cell-free (cf) DNA offers a noninvasive approach to detect mutations that may be prognostic for disease survival or predictive for primary or secondary drug resistance. A main challenge for the application of cfDNA as a diagnostic tool is the diverse mutational landscape of cancer. Here, we developed a flexible end-to-end experimental and bioinformatic workflow to analyze mutations in cfDNA using custom amplicon sequencing. Our approach relies on open-software tools to select primers suitable for multiplex PCR using minimal cfDNA as input. In addition, we developed a robust linear model to identify specific genetic alterations from sequencing data of cfDNA. We used our workflow to design a custom amplicon panel suitable for detection of hotspot mutations relevant for colorectal cancer and analyzed mutations in serial cfDNA samples from a pilot cohort of 34 patients with advanced colorectal cancer. Using our method, we could detect recurrent and patient-specific mutational patterns in the majority of patients. Furthermore, we show that dynamic changes of mutant allele frequencies in cfDNA correlate well with disease progression. Finally, we demonstrate that sequencing of cfDNA can reveal mechanisms of resistance to anti-Epidermal Growth Factor Receptor(EGFR) antibody treatment. Thus, our approach offers a simple and highly customizable method to explore genetic alterations in cfDNA.

Indexed as

Cell-Free Nucleic AcidsColorectal NeoplasmsDrug Resistance, NeoplasmHigh-Throughput Nucleotide SequencingHumansLiquid BiopsyMutationReproducibility of ResultsCell-Free Nucleic AcidscfDNAcolorectal cancerliquid biopsynext-generation sequencing

Identifiers

PMID31254442
PMCPMC6670011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.